Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Review Article

CRISPR/Cas9 Gene Editing: A Novel Approach Towards Alzheimer's Disease Treatment

Author(s): Siddhant Tripathi, Yashika Sharma, Rajesh Rane and Dileep Kumar*

Volume 23, Issue 12, 2024

Published on: 22 April, 2024

Page: [1405 - 1424] Pages: 20

DOI: 10.2174/0118715273283786240408034408

Price: $65

Abstract

In defiance of the vast amount of information regarding Alzheimer's disease (AD) that has been learned over the past thirty years, progress toward developing an effective therapy has been difficult. A neurological ailment that progresses and cannot be reversed is Alzheimer's disease, which shows neurofibrillary tangles, beta-amyloid plaque, and a lack of cognitive processes that is created by tau protein clumps with hyperphosphorylation that finally advances to neuronal damage without a recognized treatment, which has stimulated research into new therapeutic strategies. The protein CAS9 is linked to CRISPR, which is a clustered Regularly Interspaced Short Palindromic Repeat that inactivates or corrects a gene by recognizing a gene sequence that produces a doublestranded break has enchanted a whole amount of interest towards its potency to cure gene sequences in AD. The novel CRISPR-Cas9 applications for developing in vitro and in vivo models to the benefit of AD investigation and therapies are thoroughly analyzed in this work. The discussion will also touch on the creation of delivery methods, which is a significant obstacle to the therapeutic use of CRISPR/Cas9 technology. By concentrating on specific genes, such as those that are significant early- onset AD risk factors and late-onset AD risk factors, like the apolipoprotein E4 (APOE4) gene, this study aims to evaluate the potential application of CRISPR/Cas9 as a possible treatment for AD.

Keywords: Alzheimer's disease (AD), CRISPR-Cas9 technology, vector delivery systems, model for Alzheimer's disease, gene modifications, clinical models


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy